Karen Stengler
Physician Assistant · Chesapeake, VANPI 1477014835
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 85 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations.
Across 85 payments — averaging $23.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$389
- AbbVie$338
- Johnson & Johnson$270
- Axsome Therapeutics, Inc.$146
- Neurocrine Biosciences, Inc.$130
- Takeda Pharmaceuticals U.S.A., Inc.$116
- plus $650 from 12 others
What the payments were for
- Food & beverage$1,99198%
- Education$492%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,039 in reported general payments places this provider in the 80th percentile of 3,376 physician assistant providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 12 | $17,353 |
| Paliperidone ErPaliperidone | 11 | $5,030 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 112 | $3,453 |
| Methylphenidate ErMethylphenidate Hcl | 12 | $2,632 |
| Duloxetine Hcl | 38 | $1,253 |
| Oxcarbazepine | 14 | $1,097 |
| Haloperidol | 14 | $937 |
| Divalproex Sodium ErDivalproex Sodium | 26 | $660 |
| Bupropion XlBupropion Hcl | 33 | $656 |
| Trazodone Hcl | 55 | $514 |
| Bupropion Hcl SrBupropion Hcl | 16 | $469 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 19 | $455 |
| Escitalopram Oxalate | 36 | $450 |
| Fluvoxamine Maleate | 18 | $436 |
| Buspirone Hcl | 18 | $435 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $65 | $17,35312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,376 physician assistant providers in Virginia.
Other physician assistant in Chesapeake
- Lindsay SeddonChesapeake$12K
- John DalessandroSalem$160K
- Jalal AlghabraFredericksburg$119K
- Jamie GiovanelliVirginia Beach$118K
- John CarterStaunton$90K
- Melissa AlcoxNorfolk$73K
- Lindsay TomReston$71K
- Robert HigginsonRichmond$66K
- Jameka McElroy-BrooklynArlington$65K
- Hillary HartungNorfolk$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.